FAK-IN-20_product_DataBase

Bioactivity	FAK-IN-20 (Compound 7b) is an inhibitor of FAK with an IC50 value of 0.27 nM. FAK-IN-20 exhibits anticancer activity. It can arrest the cell cycle in the G2/M phase and induce cell apoptosis (apoptosis) by generating ROS[1].
Target	IC50: 0.27 nM (FAK).
Invitro	FAK-IN-20 (Compound 7b) (72 h) 在 HCT116 (结肠癌), A549 (肺癌), MDA-MB-231 (乳腺癌) 和 HeLa (宫颈癌) 等人类肿瘤细胞系中能抑制细胞增殖，IC50 值分别为 0.58、0.75、1.18、1.4 μM，具有抗癌活性[1]。FAK-IN-20 (0.2-2 μM; 24 h) 在 HCT116 细胞中将细胞周期阻滞在 G2/M 期，并通过诱导 (1-125 μM; 12 h) ROS 生成从而诱导 (0.2-25 μM; 12 h) 细胞凋亡[1]。FAK-IN-20 (1 μM; 24 h) 在 HCT116 细胞中能抑制细胞迁移[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> FAK-IN-20 相关抗体:
CAS	3004967-41-0
Formula	C27H34ClN7O5S
Molar Mass	604.12
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Li R, et al. Discovery of 2,4-diarylaminopyrimidine derivatives bearing sulfonamide moiety as novel FAK inhibitors. Bioorg Chem. 2024;144:107134.

PeptideDB